WHO Updates Essential Medicines List for Hemophilia and VWD: Louise Bannon Applauds Global Hematology Community’s Achievement
Louise Bannon, Director of Membership, Marketing and External Relations of ISTH, shared a post on LinkedIn:
”In today’s news!
WHO Updates Essential Medicines List to Improve Care for People with Bleeding Disorders
The World Health Organization (WHO) has updated its Essential Medicines List (EML) and Essential Medicines List for Children (EMLc) to better align with international clinical guidelines for the management of hemophilia and von Willebrand Disease (VWD).
These revisions will help ensure that decision makers worldwide are guided by the latest evidence when selecting and financing essential medicines, improving access to safer and more effective therapies for people with bleeding disorders (PWBDs).
Key updates include:
- New medicines added: Bi-specific monoclonal antibody emicizumab; recombinant FVIII and FIX clotting factor concentrates (CFCs)
- Existing medicines upgraded: Plasma-derived FVIII and FIX CFCs and desmopressin moved from the complementary to the core list
- Medicines removed: Pathogen-reduced and non-pathogen-reduced cryoprecipitate and Factor IX Complex (PCC)
Congratulations to the global hematology community for advocating strongly to achieve these revisions, ensuring that people with bleeding disorders have access to modern, safe, and effective therapies.
ISTH applauds the leadership of the World Federation of Hemophilia (WFH) and its partners for mobilizing this milestone effort and supporting equitable treatment access worldwide.”
Find the latest news in the World of Bleeding Disorders featured in Hemostasis Today.
-
Sep 9, 2025, 23:00Blood Podcast Alert: LSD1 Inhibitors in SCD, Ruxolitinib+Dex in HLH, Low VWF Insights
-
Sep 9, 2025, 15:47AFib: A Hidden Stroke Risk
-
Sep 9, 2025, 07:56Mortality Risk in Thrombotic Thrombocytopenic Purpura․ Insights from Laboratory Biomarkers
-
Sep 9, 2025, 06:21Vincentius Liong on Nanorobot Swarms vs Blood Clots
-
Sep 9, 2025, 05:53Noel Hiney Highlights the Value of Blood Donation and Community Support
-
Sep 10, 2025, 08:20Flora Peyvandi on Caplacizumab: Which VWF Assays Truly Measure Treatment Effectiveness?
-
Sep 10, 2025, 03:36International Journal of Stroke: Rising Incidence of Stroke in Young Adults
-
Sep 9, 2025, 19:11John Fanikos Shares Greg Piazza's Presentation On The Results of The HI-Pro Trial
-
Sep 9, 2025, 08:15Taha Ahmed Highlights Rare Case: LV Fibroelastoma Mimicking Thrombus Leading to Takotsubo
-
Sep 9, 2025, 08:14JAMA Neurology: MRI Aneurysm Wall Enhancement Predicts Risk of Intracranial Aneurysm Growth or Rupture
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 9, 2025, 10:34James Douketis Receives the 2025 Distinguished Service Award in General Internal Medicine!
-
Sep 9, 2025, 08:07Hemophilia Federation of America Launches ‘Blood Brothers’ Podcast for Men With Bleeding Disorders
-
Sep 9, 2025, 04:57World Thrombosis Day 2025: Louise Bannon Invites Donations and Partnerships
-
Sep 8, 2025, 15:10Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
-
Sep 8, 2025, 14:26European Haemophilia Consortium Marks World PT Day: Physiotherapy Empowers People with Bleeding Disorders